AstraZeneca

AI-focused health tech startups in Europe are rapidly growing, impacting future healthcare. Around 7,754 European healthcare companies use AI, with AI hiring in the sector increasing despite other areas plateauing. AI applications include R&D, clinical trials, diagnostics, and patient care. Companies like Owkin, Wandercraft, and Qureight are leading in AI-driven healthcare advancements, aiming to improve outcomes and accelerate drug development.

FDA approves AstraZeneca's FluMist nasal spray flu vaccine for self-administration, the first of its kind. The vaccine, available through a third-party online pharmacy, requires a screening and eligibility assessment. Individuals aged 2-17 should still receive it from a caregiver.

FDA approves AstraZeneca’s self-administered nasal flu vaccine FluMist for ages 2-49, citing its safety and effectiveness since 2003. The vaccine aims to increase convenience and accessibility, though it requires a prescription and has potential side effects like fever, nasal issues, and Guillain-Barré Syndrome.

FDA approves AstraZeneca's FluMist nasal spray flu vaccine for home administration, available for ages 2-49, starting next flu season. This makes FluMist the only U.S. flu vaccine that can be self-administered without a healthcare professional, ordered via an online portal, FluMist Home.

FDA approves FluMist nasal spray flu vaccine for self- or caregiver-administration for ages 2-49, the first such vaccine. It contains weakened live influenza virus strains and requires a prescription. Available through third-party online pharmacies with screening for eligibility.

FDA approves AstraZeneca’s FluMist, the first self-administered nasal influenza vaccine, available online for home use.

The FDA approved FluMist, an intranasal influenza vaccine, for self- or caregiver-administration, offering greater convenience and accessibility. This decision follows AstraZeneca's sBLA submission in Oct 2023, supported by a usability study. FluMist, already approved for ages 2-49, can now be administered by individuals or caregivers aged 18+, potentially boosting US vaccination rates.

Daiichi Sankyo launches first DTC campaign for Enhertu, 'Not Today,' airing on Amazon Prime’s Thursday Night Football, aiming to educate patients about its expanded uses. The campaign, featuring a 90-second black-and-white ad, resonates with metastatic breast cancer patients by acknowledging their struggles. Enhertu, a metastatic breast cancer drug by Daiichi Sankyo and AstraZeneca, has seen label expansions and $2.57 billion in combined sales in 2023.

FDA approves self- or caregiver-administered FluMist, the first flu vaccine not requiring healthcare provider administration. Available through third-party pharmacies, FluMist is a needle-free, intranasal option for ages 2-49, offering convenience and accessibility.

FDA approves FluMist nasal spray as the first self-administered flu vaccine for ages 2 to 49, offering greater convenience and accessibility.